Literature DB >> 24078658

Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

C Buske1, V Leblond, M Dimopoulos, E Kimby, U Jäger, M Dreyling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24078658     DOI： 10.1093/annonc/mdt298

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

1.  Autoimmune thrombocytopenia: a complication of fludarabine therapy in the treatment of Waldenstrom's macroglobulinemia.

Authors:  Yujie Jiang; Hongjuan Peng; Xin Cui; Ying Zhou; Dai Yuan; Xiaohui Sui; Lingyan Zhang; Hongzhi Xu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Paul Tappenden; Christopher Carroll; John Stevens; Emma Simpson; Praveen Thokala; Ruth Wong; Josh Wright; Rebecca Auer
Journal:  Pharmacoeconomics       Date:  2019-01       Impact factor: 4.981

Review 3.  Monoclonal IgM Gammopathy and Waldenström's Macroglobulinemia.

Authors:  Alexander Grunenberg; Christian Buske
Journal:  Dtsch Arztebl Int       Date:  2017-11-03       Impact factor: 5.594

4.  Interstitial pneumonitis related to rituximab therapy for Waldenström's macroglobulinemia.

Authors:  Xueyan Bai; Qu Cui; Yuanbo Liu
Journal:  Clin Case Rep       Date:  2014-10-06

5.  Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.

Authors:  Mark Bustoros; Romanos Sklavenitis-Pistofidis; Prashant Kapoor; Chia-Jen Liu; Efstathios Kastritis; Saurabh Zanwar; Geoffrey Fell; Jithma P Abeykoon; Kalvis Hornburg; Carl Jannes Neuse; Catherine R Marinac; David Liu; Jenny Soiffer; Maria Gavriatopoulou; Cody Boehner; Joseph M Cappuccio; Henry Dumke; Kaitlen Reyes; Robert J Soiffer; Robert A Kyle; Steven P Treon; Jorge J Castillo; Meletios A Dimopoulos; Stephen M Ansell; Lorenzo Trippa; Irene M Ghobrial
Journal:  J Clin Oncol       Date:  2019-04-16       Impact factor: 44.544

Review 6.  [Waldenström's macroglobulinemia. Current developments in diagnostics and therapy].

Authors:  A Grunenberg; C Buske
Journal:  Internist (Berl)       Date:  2016-03       Impact factor: 0.743

7.  Cost-effectiveness analysis of ibrutinib in patients with Waldenström macroglobulinemia in Italy.

Authors:  Andrea Aiello; Anna D'Ausilio; Roberta Lo Muto; Francesca Randon; Luca Laurenti
Journal:  J Mark Access Health Policy       Date:  2017-11-07

Review 8.  How I treat elderly patients with plasma cell dyscrasias.

Authors:  Maria Gavriatopoulou; Despoina Fotiou; Ioannis Ntanasis-Stathopoulos; Efstathios Kastritis; Evangelos Terpos; Meletios Athanasios Dimopoulos
Journal:  Aging (Albany NY)       Date:  2018-12-18       Impact factor: 5.682

9.  Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent.

Authors:  Naohiro Sekiguchi; Airi Hamano; Tomoko Kitagawa; Yuya Kurihara; Kenichi Ito; Miwa Kurimoto; Kozo Watanabe; Kazuhiko Hirano; Satoshi Noto; Kazuaki Yamada; Naoki Takezako
Journal:  Blood Res       Date:  2018-06-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.